Asher Biotherapeutics, Inc. announced that it will receive $54,999,990 in funding on April 3, 2024. The company will issue common shares in the transaction. The company will issue securities pursuant to exemption provided under Regulation D.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
12,179 GBX | +0.97% | +8.45% | +15.28% |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
12,182 GBX | +0.99% | +8.45% | 234B | ||
43.94 USD | -1.57% | -10.31% | 89.07B | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+15.28% | 234B | |
+34.00% | 704B | |
+27.57% | 577B | |
-7.75% | 348B | |
+18.53% | 327B | |
+4.95% | 288B | |
+4.93% | 198B | |
-9.78% | 194B | |
-4.89% | 147B | |
-11.01% | 145B |
- Stock Market
- Equities
- AZN Stock
- News AstraZeneca PLC
- Asher Biotherapeutics, Inc. announced that it expects to receive $54.99999 million in funding